MILabs’ translational imaging success is attracting more and more attention of the biopharma industry and biotech start-ups who are acquiring MILabs preclinical imaging equipment in great numbers to accelerate translation of their bench research to clinical applications. This contributes to a continues exponential growth of MILabs, mainly driven by the unique capabilities of MILabs’ in-vivo imaging platform, including the seamless integration of optical, X-ray CT, and nuclear tomography as well as ultra-high definition targeted radiotherapy imaging.
|